Cargando…

VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease

INTRODUCTION: Herpes simplex virus (HSV) may be involved in Alzheimer's disease (AD) pathophysiology. The antiviral valacyclovir inhibits HSV replication. METHODS: This phase‐II pilot trial involved valacyclovir administration (thrice daily, 500 mg week 1, 1000 mg weeks 2–4) to persons aged ≥ 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weidung, Bodil, Hemmingsson, Eva‐Stina, Olsson, Jan, Sundström, Torbjörn, Blennow, Kaj, Zetterberg, Henrik, Ingelsson, Martin, Elgh, Fredrik, Lövheim, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919248/ https://www.ncbi.nlm.nih.gov/pubmed/35310522 http://dx.doi.org/10.1002/trc2.12264

Ejemplares similares

Antiviral treatment associated with reduced risk of clinical Alzheimer's disease—A nested case‐control study
por: Hemmingsson, Eva‐Stina, et al.
Publicado: (2021)

Herpesvirus infections, antiviral treatment, and the risk of dementia—a registry‐based cohort study in Sweden
por: Lopatko Lindman, Karin, et al.
Publicado: (2021)

Long-term time trends in reactivated herpes simplex infections and treatment in Sweden
por: Lopatko Lindman, Karin, et al.
Publicado: (2022)

Urea dilution of serum for reproducible anti-HSV1 IgG avidity index
por: Olsson, Jan, et al.
Publicado: (2019)

Longitudinal Effects of Herpesviruses on Multiple Cognitive Outcomes in Healthy Elderly Adults
por: Weidung, Bodil, et al.
Publicado: (2023)

A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex–associated Alzheimer's disease
por: Lopatko Lindman, Karin, et al.
Publicado: (2019)

PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk
por: Lopatko Lindman, Karin, et al.
Publicado: (2022)

Plasma Amyloid-β in Relation to Antibodies Against Herpes Simplex Virus, Cytomegalovirus, and Chlamydophila pneumoniae
por: Lopatko Lindman, Karin, et al.
Publicado: (2021)

Herpes virus seroepidemiology in the adult Swedish population
por: Olsson, Jan, et al.
Publicado: (2017)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Temporal Dementia and Cognitive Impairment Trends in the Very Old in the 21st Century
por: Weidung, Bodil, et al.
Publicado: (2023)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Biomarkers for Microglial Activation in Alzheimer's Disease
por: Lautner, Ronald, et al.
Publicado: (2011)

HSV presence in brains of individuals without dementia: the TASTY brain series
por: Olsson, Jan, et al.
Publicado: (2016)

High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study
por: Hörnsten, Carl, et al.
Publicado: (2016)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Valacyclovir in the treatment of acute retinal necrosis
por: Taylor, Simon RJ, et al.
Publicado: (2012)

Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura
por: Bukhari, Sumera, et al.
Publicado: (2020)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Repeated lumbar punctures within 3 days may affect CSF biomarker levels
por: Olsson, Martin, et al.
Publicado: (2019)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cppvql12528omg5h6k153876qm